Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndrome
![Zealand Pharma's CEO Emanuel Dulac. | Photo: Stine Bidstrup/ERH](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12557830.ece/ALTERNATES/schema-16_9/doc7d614ndo7dino3n81np.jpg)
As a biotech firm, Zealand Pharma's first priority during Covid-19 has been to ensure that its research and development program could continue with as few alterations as possible.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.